New biomarker for erectile dysfunction: Soluble tumor necrosis factor-like weak inducer of apoptosis

sTWEAK, an inflammatory cytokine, rose with ED severity in 90 patients vs. 90 controls — AUC 0.776, 71% sensitivity and specificity

Journal: Actas Urológicas Españolas | Published: 2026-01-05 | Type: Prospective case-control study | PMID: 41500449 Authors: Iplikci A, Efiloglu O, Kado A, Erman H, Yildirim A (Istanbul Medeniyet University, Turkey — all from urology or biochemistry departments at the same institution) Funding/COI: Funding not reported. Authors declare no competing interests.

Summary

Researchers at a single Turkish university measured serum sTWEAK — an inflammatory cytokine tied to atherosclerosis — in 90 men with ED and 90 healthy controls, finding that levels climbed with disease severity. The proposed diagnostic threshold of 5.41 ng/mL yielded 71.1% sensitivity and 71.1% specificity, with an AUC of 0.776. The authors frame this as evidence that the sTWEAK pathway participates in the vascular pathogenesis of ED, not merely correlates with it — a conclusion the study design cannot support.

Claims

• sTWEAK levels were significantly higher in ED patients than in healthy controls
• Levels increased across disease severity groups (severe IIEF 1–10, moderate-mild IIEF 11–21, control IIEF 22–30)
• ROC analysis: AUC = 0.776 (p = .001); optimal cut-off 5.41 ng/mL → 71.1% sensitivity, 71.1% specificity
• ED patients had higher Beck Depression Inventory scores (p = .001) and higher erythrocyte sedimentation rate (p = .001) compared to controls

Study Quality

This is a prospective case-control study with equal group sizes (90 vs. 90), pre-specified IIEF stratification, and inclusion of relevant confounders like depression scores and inflammatory markers — reasonable scaffolding for a biomarker discovery study. Severity grading using the validated IIEF Erectile Function Domain is appropriate. However, "prospective" here means participants were enrolled and measured going forward; it does not mean this is a longitudinal study. There is no follow-up, no change in sTWEAK over time, and no functional test of whether this marker performs better than existing cardiovascular risk markers or simpler metrics like ESR.

An AUC of 0.776 is conventionally "good" but clinically marginal — particularly at a cut-off that returns symmetric 71% sensitivity and specificity. A coin flip yields 50%; this yields 71%. That leaves roughly 3 in 10 ED cases missed and 3 in 10 healthy men incorrectly flagged. The paper does not compare sTWEAK's discriminatory power against existing markers already measured in the same blood draw (ESR, CRP, lipids).

Red Flags

• Single-center, single-country sample — 90 patients from one Istanbul hospital; generalizability is unknown
• No multivariate adjustment — ED is heavily confounded by age, obesity, diabetes, hypertension, and smoking; the paper does not report whether these were controlled for in the regression
• Causal overreach — the conclusion that "sTWEAK pathway has a role in the pathogenesis of atherosclerosis in patients with ED" is not supported by a cross-sectional design; correlation is established, mechanism is assumed
• No comparison to existing markers — sTWEAK is never benchmarked against CRP or lipid panels, which clinicians already order
• Funding not disclosed — absence of disclosure is not the same as absence of funding
• Symmetrically mediocre cut-off — 71/71% at a single threshold suggests the marker is informative but not clinically decisive; no sensitivity analysis at alternative thresholds is provided

Strengths

• Prospective enrollment with a matched control group of equal size
• Validated outcome instrument (IIEF) with three-tier severity stratification
• Inclusion of Beck Depression Inventory accounts for a known confounder of ED severity reporting
• ROC analysis with explicit AUC and threshold values — the authors show their math

Verdict

This is competent exploratory biomarker work, not a diagnostic validation study. It establishes that sTWEAK is elevated in ED patients and tracks severity — a finding consistent with ED's known vascular and inflammatory biology, but not novel enough to move clinical practice. The 71% diagnostic accuracy is insufficient to justify adding a new assay when the clinical question (does this man have ED?) is already answered by the IIEF itself. The paper's value is mechanistic curiosity: it adds sTWEAK to the growing list of inflammatory molecules correlated with ED severity. A larger, multivariate, multicenter replication study would be needed before this marker earns a second look.